Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol

Mukesh Patekar, Ajay Gogia, Akash Tiwari, Lalit Kumar, Atul Sharma, Soumya Ranjan Mallick, Mehar Chand Sharma, Sanjay Thulkar, Ritu Gupta

Abstract

Background: Burkitt lymphoma (BL) is treated with short, intensive, noncross resistant multidrug chemotherapy regimens. The management of this aggressive lymphoma is a challenge in our resource-limited setting, and the published data from India is scarce. Aim: This retrospective study aims to evaluate the clinical features and treatment outcomes in adult patients with BL treated with uniform chemotherapy, cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine (CODOX-M/IVAC) protocol (+ Rituximab). Materials and Methods: The hospital records between 2011 and 2017 were reviewed to identify adult patients (age ≥18 years) who were treated with CODOX-M/IVAC protocol (+ Rituximab). The demographic and clinical details, treatment outcomes, and toxicity were recorded from the patient’s prospectively maintained case records. Results: Eighteen patients were included in this study. The median age was 38 years with male:female ratio 3.5:1. The majority of patients were high risk (14/18). All patients had extranodal site of involvement. The treatment completion rate was 83.3%. The overall response rate was 77.8% including complete response rate was 66.7%. Five patients (27%) had progressive disease on therapy. The estimated 2-year overall survival and event-free survival were 73% and 68.4%, respectively. The most common toxicity was myelosuppression (grade v3/4 neutropenia = 88.8%, grade 3/4 thrombocytopenia = 77.7%, and grade 3/4 anemia = 66.6%), febrile neutropenia was seen in 66.6% cases. Most common nonhematological toxicity was mucositis (grade 3/4 = 33.3%). No toxic death was seen. Conclusion: This one of the first retrospective analyses of treatment outcomes from India suggests that our patients are demographically and clinically similar to the western counterpart. The treatment completion rate is high despite significant toxicity. BL has a good outcome if treated adequately.

Key words: Burkitt lymphoma, cyclophosphamide, cytarabine/uniform protocol/treatment, doxorubicin, etoposide, ifosfamide, methotrexate, outcome, vincristine

Introduction

Burkitt lymphoma (BL) is a highly aggressive B-cell NonHodgkin lymphoma (NHL). It was the first tumor which was discovered to be associated with a viral infection (Epstein-Barr virus) and a chromosomal translocation which activates an oncogene (c-MYC). The BL and Burkitt leukemia is considered to be the part of the same disease spectrum.[1] WHO describes three distinct clinical forms of BL: endemic (African), sporadic (nonendemic), and immunodeficiency-associated.[1] BL is predominantly a disease of childhood, but it is also seen in the adult population. The diagnostic and therapeutic principles of BL in the adult are an extension of those used in the pediatric population.

The challenges of diagnosis and treatment of an aggressive lymphoma, like BL, is unique in low-income and resource-limited settings. The paucity of an adequate molecular diagnostic facility, trained hematopathologist, and limited access to health facility is an impediment in the adequate care of these patients. The data of the outcome of these patients from the low-income countries are sparse. Therefore, we, hereby present our experience of treating patients with BL with a uniform chemotherapy protocol from a tertiary care center in North India.

Materials and Methods

Patient information

We have retrospectively reviewed the case records of patients with BL registered in our clinics. The database included search from the digital records and case files of patients with a diagnosis of BL. We identified 22 cases of adult BL (age ≥18 years) during 2011–2017. Eighteen patients received cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine (CODOX-M/IVAC) regimen with or without rituximab (cyclophosphamide, adriamycin, vincristine, high-dose methotrexate/ifosfamide, cytarabine along with intrathecal therapy), four patients received other chemotherapy protocols and were excluded. We have included patients who received CODOX-M/IVAC (with or without Rituximab) for analysis in this study [Table 1].

Diagnostic and staging procedures

The demographic details, clinical history, physical examination, and assessment of site of involvement and staging at presentation were recorded. The complete blood cell count, lactate dehydrogenase, electrolytes, liver, and kidney function were noted at presentation. The staging workup included computed tomography scan or positron emission tomography of the whole body, bone marrow aspirate, and biopsy and cerebrospinal fluid (CSF) analysis. Clinical stage was evaluated in accordance with conventional Ann Arbor criteria. The extranodal disease was defined as a contiguous involvement of a nonlymphoid organ. Primary extranodal lymphoma was diagnosed when the initial or major site of disease was in an extranodal organ, and there was none or only regional lymph node involvement. Extensive involvement of any nonlymphoid organ system was taken as Stage IV disease, any lymph nodal mass >7.5 cm in longest diameter or a mediastinal mass occupying more than one-third of the thoracic diameter was taken as bulky disease. Toxicity of chemotherapy was assessed as per common toxicity criteria version 4.0.

Clinical response evaluation

Clinical response was classified as complete remission (CR), partial remission (PR), stable disease (SD), and progressive...
disease based on Modified Cheson lymphoma response evaluation criteria. The overall response rate (ORR) was calculated including CR and PR.\(^\text{[22]}\)

The time period from the beginning of the treatment to the date of death from any cause or to the date of the last follow-up was defined as overall survival (OS). Progression-free survival (PFS) was defined as the time from the beginning of treatment to disease progression or relapse.

**Statistical analysis**

Statistical analysis was done using IBM SPSS version 20. The Chi-square test was used to analyze the correlation between treatment regimen and achievement of response to therapy. Survival was calculated by Kaplan-Meier analysis and factors significantly affecting the survival outcomes were analyzed by Cox’s proportional hazard method. Statistical significance was defined as \(P < 0.05\).

**Results**

**Patient characteristics**

The median age at presentation was 38 years (19.0–64.0). Elderly patients (Age >60 years) constituted 11% of our study population. The majority of patients were male, with the male to female ratio being 3.5:1. The median duration of symptom duration before the presentation was 2 months (0.2–6 months). Extranodal involvement was seen in all the cases, the bone marrow was most common extranodal (9/18 [50%]). The other extranodal sites were gastrointestinal (GI) tract (8/18 [44.4%]), lung (3/18 [16.6%]), breast, adnexa, liver, central nervous system (CNS), nasopharynx, tonsillar fossa, and bone. Pleural effusion and ascites were present in 5 (27.8%) cases, respectively. The CSF cytology was negative in all cases. In our study population, 4 (22.2%) patients had Burkitt leukemia whereas one patient had primary GI Lymphoma (ileocecal region).

Majority of our patients (14/18 [77.8%]) presented with advanced stage (Stage III/IV) of disease. B-symptoms (fever, night sweat, and loss of weight or appetite) were present in 12/18 (66.6%) cases, and bulky disease was present in 9/18 (50%) of patients. 17/18 (94.5%) cases were of high-risk BL. In our study population, only one patient was HIV positive. Most of our patients had poor performance status, 10/18 (55.5%) patients had Eastern Cooperative Oncology Group performance status of \(\geq2\). Low albumin (serum albumin <3.5 g/dl) was seen in 6/18 (33.3%) cases [Table 2]. Information on fluorescence in situ Hybridization (FISH) for c-MYC (8q24) gene was available in 5/18 (27.7%) cases; of which 2/5 (40%) cases were \(t\) (8,14) positive while 2/5 (40%) cases did not reveal MYC gene rearrangement, one of these patients was tested only for \(t\) (8,14) and turned out to be negative.

Four patients underwent an initial surgery and diagnosis of BL was confirmed on histopathological examination of the surgically resected specimen. Two patients presented with acute intestinal obstruction and underwent exploratory laparotomy, biopsy, and diversion colostomy. One of the patients presented with ileocolic mass and underwent right hemicolecotomy. The 4\(^{th}\) patient presented with bilateral adnexal mass and omental deposits; she underwent exploratory laparotomy with total abdominal hysterectomy with bilateral salpingo-oophorectomy along with right hemicolecotomy.

**Treatment and outcome**

Four patients were given prephase chemotherapy with cyclophosphamide and dexamethasone. Two patients initially received one cycle of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone), each in view of the delay in the confirmed diagnosis of BL. All the 18 patients included in this study were treated with a uniform protocol using CODOX-M/

| Drug                  | Days  | Drug                  | Days  | Days  |
|-----------------------|-------|-----------------------|-------|-------|
| R                    | D2     | Cyclophosphamide      | D1     |       |
| Rituximab             | D1     | Rituximab             | D1     |       |
| Cyclophosphamide      | D1     | Etoposide             | D1     |       |
| Doxorubicin           | D10    | Methotrexate          | D1     |       |
| Methotrexate          | D1     | Methotrexate          | D1     |       |
| Intrathecal medications | IT cytarabine 70 mg | D1     |       |
|                      |        | IT methotrexate 12 mg | D3     |       |
|                      |        | IT methotrexate 12 mg | D15    |       |

\(\text{CODOX-M}\) regimen

| Drug                  | Days  | Drug                  | Days  | Days  |
|-----------------------|-------|-----------------------|-------|-------|
| R                    | D1     | Cyclophosphamide      | D2     |       |
| Ifosfamide            | D1     | Ifosfamide            | D1     |       |
| Etoposide             | D10    | Cytarabine            | D1     |       |
| Cytarabine            |       | Etoposide             | D1     |       |
| Intrathecal medications | IT methotrexate 12 mg | D1     |       |
|                      |        | IT methotrexate 12 mg | D3     |       |
|                      |        | IT methotrexate 12 mg | D15    |       |

\(\text{R-IVAC}\) regimen

Table 1: Rituximab-cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine regimen

*with granulocyte colony stimulating factor support till absolute neutrophil count > 1000/\(\mu\)l R-CODOX-M=Rituximab-cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine

\(\text{R-IVAC}\)=Rituximab–ifosfamide, etoposide, cytarabine
Table 2: Baseline clinical characteristics

| Variable          | Frequency (%) |
|-------------------|---------------|
| **Median age, years (range)** | 38 (19–64) |
| **Sex**           |               |
| Male              | 14 (77.8)    |
| Female            | 4 (22.2)     |
| **Performance status** |           |
| 0-1               | 8 (44.4)     |
| 2 or more         | 10 (55.6)    |
| **Stage**         |               |
| I + II            | 4 (22.2)     |
| III + IV          | 14 (77.8)    |
| **Risk stratification** |            |
| High risk         | 17 (94.4)    |
| Low risk          | 1 (5.6)      |
| **LDH (IU/L)**    |               |
| Normal            | 3 (16.7)     |
| Elevated          | 15 (83.3)    |
| **Serum albumin (g/dl)** |          |
| ≥3.5              | 12 (66.6)    |
| ≤3.5              | 6 (33.4)     |
| **BM status**     |               |
| Positive          | 9 (50.0)     |
| Negative          | 9 (50.0)     |
| **CSF status**    |               |
| Positive          | 0            |
| Negative          | 18 (100.0)   |

LDH=Lactate dehydrogenase, CSF=Cerebrospinal fluid, BM=Bone marrow

IVAC, of these 12 (66.6%) patients received rituximab. The ORR and complete response (CR) rate was 77.8% and 66.7%, respectively. In the subgroup of patients who received Rituximab RCODOX-M/IVAC (RCODOX-M/IVAC), the ORR and CR rate was 75.0%, and 66.6% respectively while the ORR and CR rate in the RCODOX-M/IVAC subgroup was 83.3% and 66.6%, respectively. Five (27%) patients had a progression of disease while on therapy, of these two patients developed new-onset cranial nerve palsy and on evaluation was found to have CNS disease along with nodal and medullary involvement. Of the other three patients, one patient developed new skin lesions and the other developed fulminant hepatic failure, both these patients were on evaluation confirmed to have disease progression. One patient with Burkitt leukemia had persistent bone marrow involvement despite therapy. All these five patients succumbed to their illness.

One patient had a partial response after completion of treatment; he received radiotherapy (36 Gy/20#) to residual disease. He achieved a CR after completion of radiotherapy. Out of 18 patients on RCODOX-M/IVAC, 14 high-risk patients and one low-risk patient received all 4 cycles and 3 cycles, respectively, i.e., 83.3% patients were able to complete scheduled treatment. Three high-risk patients received only 3 cycles as they had disease progression.

Toxicity

In our study, 16 (88.8%) patients had grade 3/4 neutropenia, 14 (77.7%) had grade 3/4 thrombocytopenia, 12 (66.6%) patients had febrile neutropenia, and 12 (66.6%) patients had grade 3/4 anemia. Of the nonhematologic toxicity, mucositis was the most significant toxicity, 6 (33.3%) patients developed grade 3/4 mucositis. The other nonhematologic grade 3/4 toxicity was diarrhea (15%) and transaminitis (5%).

Survival

The median event-free survival (EFS) and OS were not reached in our cohort. One-year EFS and OS was 76% and 81.1%, respectively, with a median follow-up of 15.6 months (2.5–49.2 months) [Figures 1 and 2]. The estimate 2-year EFS and OS are 68.4% and 73%, respectively. Bone marrow involvement (P = 0.01) and female gender (P = 0.01) was associated with poor OS.

Discussion

This is the first case series describing the treatment outcome of the patients of BL using a uniform protocol from India. In our series, the median age of patients was 38 (19–64), while 2/18 (11%) patients were elderly (age ≥60 years). The patients were predominantly male (3.5:1). These findings are consistent with other case series.[3,5] In some series, a higher median age (44–58 year) has also been reported.[6,7] Two earlier studies from India have reported the median age of presentation to be 22 years and 6.5 years with BL comprising 3.5% and 3% of all NHL, respectively.[8,9] However, in these two studies, pediatric BL cases were also included in this study.

In the present study, the patients have a higher frequency of B-symptoms (66.6%), a higher proportion of advanced disease (77.8%), bone marrow involvement (50%), and Burkitt leukemia (22%) subtype. CNS involvement was not seen in our case series. The majority of the patients in our study were high risk (94.5%) and bone marrow being the most common extranodal site (50%) followed by GI tract (44.4%). Studies have reported bone marrow and central nervous system (CNS) involvement in 30%–38% and 13%–17% of adults, respectively.[3,10,11]

In our study, all 18 patients received COD OX-M/IVAC regimen out of them, 12 received rituximab. The ORR and CR rate in our population was 75% and 66.6%, respectively. The 1-year EFS and OS was 76% and 81.1% respectively with a median follow-up of 15.6 (2.5–49.2) months. It is interesting that all patients who achieved CR at the end of treatment are disease free and surviving till the last follow-up. This supports the fact that though BL is an aggressive disease, once patients successfully complete treatment the long-term outcomes are good. The results of our study are comparable to the outcome of other studies using this protocol[3,4,12,13,17] [Table 3]. All of these trials used a risk- adapted approach. Two-year EFS and OS varied from 64%–92% and 67%–73%, respectively in these studies. The Dosing of COD OX-M/IVAC has varied slightly between these studies. Other regimens such as Cancer and leukemia Group B, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), Rituximab-HyperCVAD, Lymphomes Malins B (LMB) reported 2-year EFS and OS varied from 61% to 74% and 49% to 78%, respectively.[6,7,14] Dunleavy et al. reported a freedom from progression of 95% and OS of 100% at a median follow-up 86 months with DA-EPOCH regimen with rituximab.

The impact of rituximab has not been well studied in BL. Few studies reported 3-year EFS and OS in the rituximab-containing arms at 74%–76% and 77%–82%[16,18] [Table 4].

Bone marrow involvement (P = 0.01) and female gender (P = 0.01) were significantly related to poor OS. The association of poor OS with female gender could be a chance association in view of a small sample size and relatively shorter follow-up. The grade 3/4 myelosuppression was universal COD OX-M/IVAC regimen, and...
Table 3: Regimens and outcomes for the upfront therapy of Burkitt lymphoma

| Reference    | Regimen          | n  | Median age (years) | Risk     | TRM | EFS/PFS | OS    |
|--------------|------------------|----|-------------------|----------|-----|---------|-------|
| Mead et al.[3] | CODOX-M/IVAC     | 52 | 35                | High risk 77% | 5   | 2 years EFS 65% | 2 years OS 67% |
| Mead et al.[4] | CODOX-M/IVAC     | 53 | 37                | High risk 79% | 9   | 2 years EFS 64% | 2 years OS 67% |
| Magrath et al.[12] | CODOX-M/IVAC | 41 | 25                | High risk 83% | 0   | 2 years PFS 92% | NA    |
| Lacasse et al.[13] | CODOX-M/IVAC | 14 | 47                | High risk 78% | 0   | 2 years EFS 64% | 2 years OS 71% |
| Barnes et al.[17] | CODOX-M/IVAC | 46 |                   | High risk 84% | NA  | 3 years PFS | 3 years OS |
|              | With R           | 40 |                   |           |     | 74%     |       |
|              | Without R        | 40 |                   |           |     | 61%     | 66%   |

EFS=Event-free survival, PFS=Progression-free survival, OS=Overall survival, CODOX-M/IVAC=Cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine, NA=Not available, TRM= treatment related mortality, R= rituximab

Table 4: Other regimens and outcomes for the upfront therapy of Burkitt lymphoma

| Author       | Regimen          | n  | Median age (years) | Risk   | TRM | EFS/PFS | OS    |
|--------------|------------------|----|-------------------|--------|-----|---------|-------|
| Rizzieri et al.[9] | CALGB regimen | 105 | 44                | IPI ≥3, 47% | 7   | 2-year EFS 74%   | 3-year OS 58% |
| Thomas et al.[7]  | Hyper CVAD          | 26 | 58                | High LDH 70% | 5   | 3-year CCR 61%   | 3-year OS 49% |
| Diviné et al.[14] | LMB regimen        | 72 | 33                | High LDH 60% | 0   | 2-year EFS 65%   | 2-year OS 70% |
| Dunleavy et al.[15] | DA-EPOCH            | 19 | 25                | High LDH 37% | 0   | EFS 95%**      | OS 100%** |
| Ribrag et al.[16]  | LMBA regimen        | 128 | 47                | High LDH 75% | 9   | 75%      | 83%   |
|              | With R             | 129 |                   |         |     | 62%     | 70%   |
| Thomas et al.[18]  | R-hyper CVAD        | 31 | 46                | High LDH 100% | 1   | 3-year EFS 80%  | 3 years OS 89% |

**Median follow-up 86 months. EFS=Event-free survival, PFS=Progression-free survival, OS=Overall survival, CALGB=Cancer and leukemia Group B, R-hyper CVAD=Rituximab-hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, DA-REPOCH=Dose-adjusted rituximab, etoposide, vincristine, cyclophosphamide, doxorubicin, LDH=Lactate dehydrogenase, TRM = Treatment related mortality, IPI = International prognostic index, CCR = continuous complete response, LMB= Lymphomas Malins B

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.
2. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
3. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphomas: Results of United Kingdom lymphoma group LY06 study. Ann Oncol 2002;13:1264-74.
4. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, et al. A prospective clinicopathologic study of dose-modified CODOX-M/ IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248-60.
5. Boerma EG, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC, et al. Gender and age-related differences in Burkitt lymphoma – Epidemiological and clinical data from the Netherlands. Eur J Cancer 2004;40:2781-7.
6. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and leukemia group B study 10002. Br J Haematol 2014;165:102-11.
7. Thomas DA, Cortes J, O’Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD-program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-70.
8. Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: Analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013;54:1004-11.
9. Sahni CS, Desai SB. Distribution and clinicopathologic characteristics of non-Hodgkin’s lymphoma in India: A study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma 2007;48:122-33.
10. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-20.
11. McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD, South Asian Journal of Cancer ● Volume 7 ● Issue 3 ● July-September 2018

Figure 1: Event-free survival in Burkitt lymphoma

Figure 2: Overall survival in Burkitt lymphoma

it was the most common toxicity in our series. However, despite significant toxicity related to this regimen, the protocol completion rate in our series was 83.3%, which is comparable with western literature.[12,18] There were no toxic deaths in this case series. A large proportion of our patients were diagnosed of having BL based on morphology and immunohistochemistry. The molecular evidence through FISH was available in only five (27%) patients. In our resource-limited setting, the availability of FISH for MYC rearrangement hampers adequate molecular diagnosis of these patients.

Our study is limited by its small sample size, short follow-up, and retrospective study design. Despite, of these limitations, it gives us a window of opportunity to see the outcomes and toxicity of our patients who are treated with aggressive chemotherapy protocol like CODOX-M/IVAC.

Conclusion

Our patients of BL treated with CODOX-M/IVAC protocol are able to complete treatment despite significant toxicity. The outcomes of these patients are comparable to those in the western population. The bone marrow involvement at baseline was found to be a poor outcome predictor in our series which needs verification in larger series.

Patekar, et al.: Outcome of adult Burkitt lymphoma with uniform treatment protocol
et al. Effective treatment of small-non-cleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol 1991;9:941-6.
12. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-34.
13. Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leuk Lymphoma 2004;45:761-7.
14. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, et al. Burkitt lymphoma in adults: A prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005;16:1928-35.
15. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 2013;369:1915-25.
16. Ribrag V, Koscielny S, Bouabdallah K, Salles G, Casasnovas O, Fornecker LM, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:2402-11.
17. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: A retrospective analysis. Ann Oncol 2011;22:1859-64.
18. Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-80.